LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.16) per share which missed the analyst consensus estimate of $(0.96) by 20.83 percent. This is a 152.17 percent decrease over losses of $(0.46) per share from the same period last year. The company reported quarterly sales of $1.588 million which missed the analyst consensus estimate of $1.886 million by 15.81 percent.